摘要
抗血管生成在恶性肿瘤治疗中的作用日益突出,其在转化、维持治疗过程中都发挥重要作用。我国自主研发的抗血管生成靶向药甲磺酸阿帕替尼(apatinib,YN968D1)已批准用于晚期胃腺癌或胃-食管结合部腺癌的三线及三线以上的治疗,并在多个实体肿瘤中探索应用。随着对阿帕替尼研究的深入,其安全性问题受到广泛关注。本文重点介绍了阿帕替尼在临床应用中常见的不良反应,综合分析了现有的临床数据,对比了阿帕替尼与其他常用抗血管生成药物不良反应的优劣,以期帮助临床医生更好地把握该药的安全性,从而为患者提供更加安全、有效的治疗。
Antiangiogenic targeted therapy plays an important role in the treatment of malignant tumors, especially in the process of antitumor treatment including transformation stage, late stage, and maintenance stage. Apatinib (YN968D1) is a self-developed antiangiogenic targeted agent that was approved and launched for third-line and subsequent-line treatment for advanced gastric adenocarcinoma or gastro-esophageal junction adenocarcinoma. Moreover, the use of apatinib for other multiple solid tumors has been investigated. With an increase in the number of clinical studies on apatinib, concerns have been raised about its safety. Hence, we highlight the common adverse reactions of apatinib in clinical application and the incidences of various adverse events in different tumor treatments. We provide a comprehensive analysis of available clinical data and compare the advantages and disadvantages of apatinib with other common antiangiogenic drugs regarding their adverse reactions. Overall, these results will help to provide a better understanding of the safety of this medicine in the hope of helping physicians to provide patients with a safe and effective treatment.
作者
时佳琪
刘超
张艳桥
张纯慧
Jiaqi Shi, Chao Liu, Yanqiao Zhang, Chunhui Zhang(The Eighth Ward of Oncology Department of Harbin Medical University Cancer Hospital, Harbin 150081, Chin)
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2018年第4期191-195,共5页
Chinese Journal of Clinical Oncology
基金
国家自然科学基金项目(编号:81672428)
中国医疗手牵手工程委员会和北京医学奖励基金会项目(编号:353)
北京希思科临床肿瘤学研究基金(编号:Y-MX2016-027)资助~~
关键词
阿帕替尼
恶性肿瘤
抗血管生成治疗
不良反应
靶向药
apatinib, malignant tumor, antiangiogenic targeted therapy, adverse reactions, targeting drugs